A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis
Status:
Completed
Trial end date:
2021-04-15
Target enrollment:
Participant gender:
Summary
This will be a multicenter, double-blind, double-dummy, placebo controlled, randomized study
to evaluate efficacy and safety of AUR101 (RORgamma inhibitor) in patients with
moderate-to-severe psoriasis.
Approximately 90 patients with chronic moderate-to-severe plaque psoriasis will be randomized
to the 2 dose groups of AUR101 and one group of Placebo. The patients will receive the
treatment for 12 weeks.